In the SURMOUNT-1 Trial (a study on obesity), participants lost up to 24.2% of their body weight over 48 weeks the most significant weight reduction seen in an anti-obesity medication to date
Fourth, the duration of the trial, 32 weeks, was insufficiently long to demonstrate the durability of glycemic and weight effects of CagriSema [10]
Pricing: $99 first month (save $100), then $199-$349 depending on tier Best For: Nocatee residents wanting proven, medically supervised weight loss close to home
E-Posters - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P2586 - ESOC25-1678 ATYPICAL PRESENTATIONS IN CADASIL: INTRACRANIAL HAEMORRHAGE AS INDEX PRESENTATION Monturayo Wadzani 1 , Mark Maskery 1 , Amna Sajjad 1 , Mohamed Attia 1 , Ayesha Muneer 1 , Kirsty Ward 1 , Syeda Ismail 1 , Simina Cozma 1 , Dwaipayan Sen 1,2 1 Greater Manchester Comprehensive Stroke Centre, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford Royal Hospital, Manchester, United Kingdom, 2 Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom Background and Aims: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) caused by pathogenic mutations in NOTCH 3 gene is a leading cause of monogenic cerebral small vessel disease resulting in ischaemic strokes and vascular dementia
2011 Mar;11(1):1-9
